Online citations, reference lists, and bibliographies.
← Back to Search

18F-FDG PET/CT In Therapy Response And In Predicting Responders Or Non-responders In Malignant Pleural Mesothelioma Patients, By Using Semi-quantitative MRECIST And EORTC Criteria.

A. Niccoli Asabella, Alessandra Di Palo, C. Altini, M. Fanelli, C. Ferrari, V. Lavelli, G. Ranieri, C. Gadaleta, G. Rubini
Published 2018 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
OBJECTIVE To evaluate the role of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in therapy response assessment according modified response evaluating criteria of solid tumors (mRECIST) and the predictive role of volume-based semi-quantitative parameters in patients with malignant pleural mesothelioma (MPM). Furthermore modified RECIST criteria for MPM mRECIST and the European Organization for Research and Treatment of Cancer (EORTC) criteria were compared and the predictive role of 18F-FDG PET/CT in the post-therapy outcome. SUBJECTS AND METHODS Thirty five selected patients with MPM underwent 18F-FDG PET/CT scan at baseline (1) and after therapy (2). Semi-quantitative 18F-FDG PET/CT parameters were collected for each scan and also differences (Δ) ΔSUVmax, ΔSUVav, ΔMTV, ΔTLG, response index (RI)max% and RIav% were evaluated. Radiologic response to therapy was assessed by using the mRECIST and EORTC. RESULTS The correlation between response to therapy assessed by EORTC and mRECIST criteria was moderate (K=0.418; 95%CI:0099-0736). According to mRECIST, statistical differences between responders and non-responders were significant in the analysis of semi-quantitative parameters. According mRECIST criteria, all parameters defined a good area under the curve (AUC) but the better AUC resulted for ΔMTV (cut-off≤11.3, sensitivity=91.3%, specificity=91.7%) and ΔTLG (cut-off≤59.1, sensitivity=82.6%, specificity=100%). Kaplan-Meier curves between responders and non-responders did not show statistically significant differences. CONCLUSION The semi-quantitative analysis of 18F-FDG PET/CT has an important role in MPM therapy response assessment and has a predictive role in distinguishing responders and non-responders.
This paper references
10.1967/s002449910162
Feasibility and performance of an adaptive contrast-oriented FDG PET/CT quantification technique for global disease assessment of malignant pleural mesothelioma and a brief review of the literature.
V. A. Marín-Oyaga (2015)
10.1016/j.lungcan.2009.04.015
Combined FDG-PET/CT in response evaluation of malignant pleural mesothelioma.
P. Veit-Haibach (2010)
10.1118/1.1688211
Measurement of mesothelioma on thoracic CT scans: a comparison of manual and computer-assisted techniques.
S. Armato (2004)
10.1002/SSU.2980110507
Intracavitary photodynamic therapy for malignant pleural mesothelioma.
H. Takita (1995)
10.1016/S0169-5002(07)70156-3
Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose.
G. Ceresoli (2006)
10.1016/S0022-5223(99)70469-1
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
D. Sugarbaker (1999)
10.1016/j.ejrad.2010.11.006
Continued pemetrexed and platin-based chemotherapy in patients with malignant pleural mesothelioma (MPM): value of 18F-FDG-PET/CT.
N. Schaefer (2012)
10.1038/sj.bjc.6690105
The European mesothelioma epidemic
J. Peto (1999)
10.2967/jnumed.107.042333
Early Prediction of Response to Chemotherapy and Survival in Malignant Pleural Mesothelioma Using a Novel Semiautomated 3-Dimensional Volume-Based Analysis of Serial 18F-FDG PET Scans
R. Francis (2007)
10.1967/s002449910136
Can 3'-deoxy-3'-(18)F-fluorothymidine or 2'-deoxy-2'-(18)F-fluoro-d-glucose PET/CT better assess response after 3-weeks treatment by epidermal growth factor receptor kinase inhibitor, in non-small lung cancer patients? Preliminary results.
Amit Bhoil (2014)
10.1378/CHEST.103.4_SUPPLEMENT.373S
Natural history and epidemiology of malignant mesothelioma.
K. Antman (1993)
10.1967/s002449910551
Can semiquantitative measurements of SUVmax and cut-off values differentiate colorectal malignant from benign lessions?
T. Nguyen (2017)
10.1510/icvts.2010.255901
Does positron emission tomography offer prognostic information in malignant pleural mesothelioma?
S. Sharif (2011)
10.1089/HUM.1998.9.7-1083
Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma.
D. Sterman (1998)
10.1967/s002449910409
Update of the role of PET/CT and PET/MRI in the management of patients with cervical cancer.
Benjapa Khiewvan (2016)
10.1245/s10434-010-1107-z
Volume-Based Parameter of 18F-FDG PET/CT in Malignant Pleural Mesothelioma: Prediction of Therapeutic Response and Prognostic Implications
H. Lee (2010)
10.1967/s002449910557
The value of 18FDG PET/CT parameters, hematological parameters and tumor markers in predicting KRAS oncogene mutation in colorectal cancer.
A. Oner (2017)
10.1016/S0025-6196(12)65411-1
Malignant mesothelioma of the pleura.
R. J. Pisani (1988)
10.1016/J.JAMCOLLSURG.2004.02.024
Sequential preoperative fluorodeoxyglucose-positron emission tomography assessment of response to preoperative chemoradiation: a means for determining longterm outcomes of rectal cancer.
J. Guillem (2004)
10.1016/J.LUNGCAN.2003.07.005
Inadequacy of the new Response Evaluation Criteria in Solid Tumors (RECIST) in patients with malignant pleural mesothelioma: report of four cases.
F. Monetti (2004)
10.1007/s00259-018-4056-6
FDG PET-derived parameters as prognostic tool in progressive malignant pleural mesothelioma treated patients
E. Incerti (2018)
10.1016/J.LUNGCAN.2005.03.030
CT, RECIST, and malignant pleural mesothelioma.
A. Nowak (2005)
10.1016/S0959-8049(99)00229-4
Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.
H. Young (1999)
10.1002/ijc.23874
Survival of pleural malignant mesothelioma in Italy: A population‐based study
F. Montanaro (2009)
10.1016/j.radonc.2010.07.003
Segmentation of positron emission tomography images: some recommendations for target delineation in radiation oncology.
J. Lee (2010)
10.1007/s00261-014-0277-8
Comparison of 18F-FDG PET/CT methods of analysis for predicting response to neoadjuvant chemoradiation therapy in patients with locally advanced low rectal cancer
C. Altini (2014)
[New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)].
H. Watanabe (2009)
10.2214/AJR.13.10572
FDG PET/CT in the management of primary pleural tumors and pleural metastases.
Matthew J. Kruse (2013)
10.1016/S1095-0397(99)00016-3
Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging. The Visual Response Score and the Change in Total Lesion Glycolysis.
S. Larson (1999)
10.1007/s11307-010-0426-6
Current Evidence Base of FDG-PET/CT Imaging in the Clinical Management of Malignant Pleural Mesothelioma: Emerging Significance of Image Segmentation and Global Disease Assessment
S. Basu (2010)
10.1097/MD.0000000000000864
18F-FDG PET/CT Role in Staging of Gastric Carcinomas: Comparison with Conventional Contrast Enhancement Computed Tomography
C. Altini (2015)
10.1007/s00259-014-2960-y
Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma
E. Lopci (2014)
10.1093/ANNONC/MDH059
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.
M. Byrne (2004)
Volumetric analysis of 18F-FDG PET in glioblastoma multiforme: prognostic information and possible role in definition of target volumes in radiation dose escalation.
K. Tralins (2002)
10.1016/S0169-5002(03)00292-7
Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma.
R. V. van Klaveren (2004)
10.1016/j.lungcan.2013.08.005
Imaging in pleural mesothelioma: a review of the 11th International Conference of the International Mesothelioma Interest Group.
S. Armato (2013)
10.2214/AJR.172.4.10587144
Staging of malignant pleural mesothelioma: comparison of CT and MR imaging.
R. Heelan (1999)
10.2214/AJR.05.0076
Variability in mesothelioma tumor response classification.
S. Armato (2006)
Revised Modi ed Response Evaluation Criteria in Solid Tumors for Assessment of Response in Malignant Pleural Mesothelioma (Version 1.1)
Armato SG 3rd (2018)
10.1016/j.clinimag.2013.06.009
18F-FDG PET/CT in suspected recurrences of epithelial malignant pleural mesothelioma in asbestos-fibers-exposed patients (comparison to standard diagnostic follow-up).
A. Niccoli-Asabella (2013)
10.2214/AJR.155.5.2120965
Malignant pleural mesothelioma: CT manifestations in 50 cases.
A. Kawashima (1990)
10.1967/s002449910510
An imaging target TGF-β1 for hepatocellular carcinoma in mice.
Y. Zhang (2017)
10.1016/S1095-0397(00)00041-8
Tumor Burden Assessment with Positron Emission Tomography with
Akhurst (2000)
10.1158/1078-0432.CCR-08-3290
Metabolic Tumor Volume of [18F]-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Predicts Short-Term Outcome to Radiotherapy With or Without Chemotherapy in Pharyngeal Cancer
M. Chung (2009)
10.1016/J.ACRA.2005.05.021
Evaluation of semiautomated measurements of mesothelioma tumor thickness on CT scans.
S. Armato (2005)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar